Olive oil is the primary source of fat in the Mediterranean diet, which is associated with a significant improvement in health status, as measured by reduced mortality from several chronic diseases. The current pandemic of obesity, metabolic syndrome, and type 2 diabetes is intimately associated with an atherogenic dyslipidemic phenotype. The core components of the dyslipidemia of the metabolic syndrome, which most likely initiate atherosclerosis, are the "lipid triad" of high plasma triglycerides, low levels of high-density lipoproteins, and a preponderance of small, dense low-density lipoproteins at fasting. However, postprandial (non-fasting) TG (postprandial hyperlipidemia) are also recognized as an important component for atherosclerosis. Herein, the purpose of this review was to provide an update on effects and mechanisms related to the olive oil on postprandial hyperlipidemia and its implications for the onset and progression of atherosclerosis and metabolic syndrome. 2 Extra virgin olive oil is a virgin olive oil whose free acidity, expressed as oleic acid, is not more than 0.8 gram per 100 grams and organoleptic characteristics (flavour and colour) are excellent (for olive oil classification and definitions see Ref.
hydrocarbons, ketones, furans, and others). This fraction contains important bioactive compounds. Table 1) . Carbon chains containing 2 or more cis double bonds, with the first double bond located between either the 3 rd and 4 th or the 6 th and
Brief description of olive oil composition
Oleic acid is the primary component of virgin olive oil (≈83% oleic acid in position sn−2 of the triglycerides, TGs) and is also found in peanut oil (≈59% oleic acid) and canola oil (≈37% oleic acid). Oleic acid is a key component of TGs and membrane lipids. 7 Importantly, oleic acid is the most common FA in nature, as well as in our diet (generally, oleic acid supplies an amount of calories equivalent or greater than the amount provided by SFAs and PUFAs combined). Tight restrictions on SFA consumption (<10% of total daily calories; less than 7% for high-risk individuals) and PUFA consumption (<5%) have been recommended. By contrast, oleic acid may provide up to 20-25% of total daily calories.
The unsaponifiable fraction of virgin olive oil contains highly bioactive compounds (>200 constituents) ( Table 2) . Despite their wide variety and nutritional significance, they commonly account up to 3% of the total oil composition (reaching individual concentrations as smaller as ppm). 8 This fraction is fundamental in contributing to specific characteristics of virgin olive oil, such as its oxidative stability and its special flavour (aroma and taste) as well as its colour. During gastric lipolysis, FFAs have higher affinity for the surface than the core of the lipid droplets. 13 There is a considerable fusion between lipid droplets, probably due to the presence of FFAs, monoglycerides (MGs), and diglycerides (DGs) that are known to be fusogenic. This change in the lipid composition of the droplet surface during lipolysis could modify the interfacial tension or the surface pressure and could then interfere with gastric lipase binding and activity. 14 The accumulation of FFAs at the droplet surface leads to an inhibition of lipolysis by gastric lipase. The mechanism by which this happens is attributed to the formation of clusters at the surface of the lipid droplets. In the intestine, the smaller size of lipid droplets increases proportionally the lipid surface exposed to the pancreatic lipase. 
Assembly of intestinal lipoproteins containing triglycerides from olive oil ingestion
In the enterocyte, FFAs (mainly oleic acid) from absorption and the pool of endogenous metabolism, together with sn-2 MGs, are used for re-synthesis of TGs.
This process is initiated with the activation of FFAs to the corresponding acyl-CoA.
In this form, FFAs are sequentially transferred to sn-2 MGs by MG and DG acyltransferases. These enzymes form a complex called ''triglyceride synthetase'', 23 and the pathway favours the stereospecific reacylation at the sn-1 position. It contributes to 80% of the intestinal TG re-synthesis in the fed state. Acyl-CoA can also be transferred to α-glycerophosphate (derived from glucose metabolism) by the phosphatidic acid pathway, which accounts for the remaining 20%. 21 The composition of these novel TGs closely resembles the composition of TGs from olive oil. 24 These
TGs are coated with cholesterol, PLs, and one molecule of apolipoprotein (apo) B48
at the rough and smooth endoplasmic reticulum in a microsomal TG transfer protein (MTP)-dependent step, 25 and further processed in the Golgi apparatus before being released as chylomicrons (CMs) by the enterocyte through exocytosis. It occurs through the basolateral membrane of enterocytes and CMs enter the lymphatic capillaries of intestinal microvilli that drain into lymphatic channels, reaching the systemic circulation through the thoracic duct. 26 The body can also secrete very lowdensity lipoproteins (VLDLs). While CMs are of intestinal origin and formed after the ingestion of fatty meals, VLDLs are the major lipoproteins secreted by the liver during fasting. 21 Both CMs and VLDLs are considered TG-rich lipoproteins (TRLs).
POSTPRANDIAL HYPERLIPIDEMIA Generalities
Postprandial hyperlipemia is a normal and transient physiological TGs to the incidence of CVD events or deaths. 41 Many patients with CVD remain at high risk for CVD events even when the LDL-C goal has been achieved with lipidlowering therapy. 42 These lines of evidence indicate that non-fasting levels of plasma TGs may be predictive and independent of traditional LDL-C-related risk of CVD.
Postprandial hyperlipemia and metabolic syndrome
Metabolic syndrome (MetS) is a major and escalating public health and clinical challenge worldwide in the wake of urbanization, surplus energy intake, increasing obesity, and sedentary life habits. It is estimated that around 20-25% of the world's adult population has MetS. In Spain, a national survey reported that the prevalence of MetS reached up to 30% in 2010 (Figure 6) . 43 (Tables 3 and 4) .
The core components of the atherogenic dyslipidemia in MetS are the "lipid triad" of high plasma TGs, low levels of HDL-C, and a preponderance of small, dense LDL-C at fasting. 56, 57 Several studies have described abnormalities during the postprandial state in patients with CHD, 58 showing that non-fasting TGs is an independent predictor of CHD in multivariate analysis, 59 even after adjustment for fasting TGs or HDL-C in normolipidemic men. Elevated non-fasting TGs are often found in insulin-resistant subjects. Some reports have indicated that postprandial hyperinsulinemia and/or decreased insulin sensitivity are also involved in altered acute metabolism of dietary fats. 60 The decreased insulin sensitivity commonly associated with obesity 61 and the fat abdominal accumulation 62 may well play an important part in the development of MetS.
One challenge aspect of MetS is to understand the cellular mechanisms that link the metabolic abnormalities with the pathophysiological effects that generate this disease. One important link has been derived from the finding that proinflammatory cytokines are overexpressed during fat abdominal accumulation, which later will lead to several obesity-related disorders. 63 Adipose tissue is a heterogeneous mix of adipocytes, stromal pre-adipocytes, immune cells, and endothelium, which can respond rapidly and dynamically to alterations under nutrient excess through adipocyte hypertrophy and hyperplasia. 64 With obesity and progressive adipocyte enlargement, the blood supplied to adipocytes may be reduced with consequent hypoxia. 65 This condition of inadequate oxygen supply has been proposed to be an inciting aetiology of adipocyte necrosis and macrophage infiltration into adipose tissue, leading to an overproduction of pro-inflammatory factors (e.g., adipokines)
and to a local inflammation that propagate an overall systemic inflammation associated with the development of obesity-related comorbidities. 66 Tumour necrosis factor-alpha (TNF-α), adiponectin, visfatin/NAMPT (nicotinamide phosphoribosyltransferase), and interleukin-6 (IL-6) are among the most important adipokines involved in the pathogenesis of MetS and produced by adipocytes and by infiltrated macrophages into adipose tissue. 67 TNF-α is a pro-inflammatory cytokine that exerts numerous effects in adipose tissue including on lipid metabolism and insulin signalling. An increase in TNF-α promotes the secretion of other pro-inflammatory cytokines, such as IL-6, and reduces the production of anti-inflammatory cytokines, such as adiponectin. 68 There is evidence suggesting that TNF-α may induce apoptosis in adipocytes 69 and may promote peripheral insulin resistance by the inhibition of the insulin receptor substrate 1 signalling pathway. 70 Adiponectin exerts an anti-inflammatory activity and modulates insulin sensitivity by stimulating glucose utilization and FA oxidation. 71 Adiponectin is almost exclusively secreted by adipose tissue. Its levels decrease in obesity and are inversely correlated with visceral adipose tissue accumulation. 72 Visfatin/NAMPT is a protein with several functions. Although the first discovery of this molecule as a pre-B-cell colony-enhancing factor suggested primarily a cytokine function, its rediscovery as the key enzyme in nicotinamide (NAM) adenine dinucleotide (NAD + ) generation has considerably widened its potential biological activities. 73 Although originally produced in adipose tissue by adipocytes and infiltrating macrophages, it seems to be secreted by other cells and tissues such as skeletal muscle, liver, immune cells, cardiomyocytes, and brain. 74 Visfatin/NAMPT has a broad spectrum of effects and is mirrored by its potential involvement in a wide range of disorders, including MetS, myocardial failure, atherosclerosis, inflammatory diseases, malignancies, neurodegenerative disorders, and aging. 75 IL-6 is a multifaceted, pleiotropic cytokine that is a central player in the regulation of inflammation, haematopoiesis, immune responses, and host defence mechanisms. 76 Because one-third of circulating IL-6 in healthy individuals is estimated to originate from adipose tissue, IL-6 is considered an adipokine. Moreover, IL-6 has been found to be crucial in immunoregulation. It can itself enhance leukocyte differentiation and proliferation, immunoglobulin secretion, acute phase protein production, and macrophage/monocyte activation. IL-6 is considered as an early key factor that triggers acute phase reactants and metabolic abnormalities tightly associated to inflammatory responses.
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Pharmacological approaches affecting postprandial hyperlipemia
The large majority of drugs affecting lipid metabolism also affects postprandial hyperlipemia; however, well-designed and robust clinical studies in this specific field are limited due the difficulties of setting up a postprandial study in a large cohort of patients.
Improved understanding of the physiology and genetic regulation of postprandial TG metabolism could lead to the identification of new targets for therapy. 78 However, data from randomized clinical trials on the benefits of lowering TGs are much less robust than for the benefits of lowering LDL-C with statins as inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. 79, 80 This could be due to the lack of high-grade evidence for benefits of TG-lowering drugs, which is reflected by the lack of specific target goals for both fasting and non-fasting levels of MetS and T2D. 86 Available data have pointed that statins also reduce non-fasting levels of plasma TGs. 87 Interestingly, ezetimibe has been reported to reduce apoB48 secretion in human intestine, suggesting a direct effect of this drug on assembly of postprandial TRLs in enterocytes. 88 Studies on fibrates have given consistent results reporting significant lowering of non-fasting levels of plasma TGs in response to a standardized fat challenge. 28,88 Furthermore, fenofibrate also reduced levels of plasma apoB48 and biomarkers for postprandial TRL remnants. 89 New pharmacological and non-pharmacological approaches, such as dual peroxisome proliferator-activated receptor (PPAR)α/PPARδ agonists, dietary oils rich in DGs, inhibitors of DG-O-acyltransferase-1, and microsomal TG transfer protein, antisense oligonucleotides for apoB100, apoB48, and apoCIII, and incretinbased treatments could be employed alone or in combination with conventional therapies to optimize treatment for management of dyslipidemia due to high fasting and non-fasting levels of plasma TGs. 28 However, the clinical efficacy, mechanisms of action, safety, and tolerability of these newer agents requires further testing in clinical trials.
Conclusions
MetS is a major and escalating public health and clinical challenge worldwide in the wake of urbanization. The complexity of the molecular pathophysiology of MetS requires rational therapeutic and dietary strategies. Olive oil is a natural fruit product that contains a unique composition of oleic acid and minor constituents. Within this context, the consumption of olive oil has shown a broad range of promising activities in the postprandial disturbances. Nonetheless, further efforts are needed to mechanistically define the biochemical and biological postprandial activities of olive oil on atherosclerosis and MetS.
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